Ashland Inc. ASH

Key data

The business

Ashland makes specialty ingredients, not bulk chemicals. Inside a pill, its cellulose polymers bind the powder and control how fast the drug releases. In shampoo and lotion, its ingredients set the thickness and the feel on skin. In paint, its additives stop drips. Customers design these into their formulas, and getting a rival ingredient re-approved, especially in regulated pharma, is slow and costly. That switching pain is the moat. The catch is that one of four segments, Intermediates, makes commodity solvents (BDO and NMP) with none of that stickiness, and it is exactly what management has been shrinking and writing down. Revenue fell from $2.39B in FY2022 to $1.82B in FY2025, part weak demand, part deliberate pruning and divestiture. What is left skews toward the ingredients customers cannot easily replace. Just 2,900 employees run a company worth $3.3B, a tell of how automated and asset-heavy the plants are.

The numbers

The quarters show a business coming off the floor. Q3 2025 carried a roughly $700M impairment that buried the print; strip it and the sequence since is a steady climb in revenue and a sharp recovery in gross profit.

Revenue grew 7.3% year over year in the June quarter and 3.1% sequentially, the highest quarterly sales since the shrink began. The fiscal-year view is uglier, because it holds the FY2025 loss and the FY2022 divestiture gain that flatter and distort the ends.

The cash story diverges hard from the reported one. Over three years revenue compounded down 8.6% while the share count fell 17.9%, so revenue per share held far better than the top line. GAAP went to an $845M loss on impairments, yet free cash flow stayed real at $7.02 per share over the last year, a 9.7% yield at today's price. That gap, near-zero reported profit against a 9.7% cash yield, is the whole debate: buy a cash machine at ten times its free cash flow if the write-offs are behind, or watch restructuring keep eating the cash if they are not. The lens that decides it is gross margin, which is finally healing.

The market prices Ashland as a shrinking commodity chemical maker. The print that settles it is whether gross margin holds above 30% now that customer destocking has passed.

Management

The buyback record is the honest indictment. Ashland spent $1.33B repurchasing stock across 2021 through 2024 at average prices of $89 to $101, then slowed to just $100M in 2025 near the $55 low, the one year the stock was actually cheap. That is buying dear and going quiet at the bottom, the opposite of the discipline the shrink-to-quality strategy implies. Share count is down 17.9%, but paid for at the wrong prices. There were no open-market insider buys or sells in the last twelve months, so no one put personal money behind the turn. CEO Guillermo Novo earned $9.0M in FY2024 compensation; the guidance record is a coin flip, beating adjusted estimates in two of the last four quarters and missing the other two. The pay rewards the reshaping, not yet the result.

How it fails or surprises you

The recovery is destocking noise, not demand. The June gross-margin bounce to 31% could be customers refilling shelves after a lean year rather than end-demand returning. If quarterly revenue slips back below $460M and margin softens, the 22x adjusted multiple has no earnings growth beneath it. The print to watch is Q4 2026 revenue holding above $490M.

"One-time" has become the run-rate. TTM net income is only $52M on $1.84B of revenue, a 2.8% margin, and this is the fourth straight year of restructuring charges. The bull says cash is the truth and GAAP is noise; the risk is that charges recur in FY2027 and the 9.7% cash yield never reaches shareholders cleanly. This is the fact the cheap-on-cash read explains least.

Pharma ingredient demand re-accelerates (right tail). If Life Sciences excipients inflect, riding the oral-drug and GLP-1 formulation wave, the sticky high-margin revenue the market ignores shows up as gross margin above 33%. The market values Ashland as a fading commodity house; a pharma-supply volume surge reveals a franchise it is not paying for. Watch Life Sciences segment growth and margin.

Closing thoughts

This is the case where a specific print resolves it, and the print has started to arrive. The re-rate the setup was waiting on earlier this year has partly happened: the stock ran from a mid-$40s trough to $73 as Q3 delivered the first clean quarter of margin recovery and a 7% sales gain. So the easy money, cheap with no catalyst in sight, is gone; what remains is whether two more quarters confirm the demand is real. The left tail is contained, net debt is 2.7 times EBITDA, the current ratio is 3.0, and free cash flow is positive, so this is not a survival question. It is a durability question, and my read is modestly favorable with the odds now closer to even than they were at $46.

The bet comes back to whether Ashland's sticky ingredients, the pill binders and the shampoo thickeners, keep earning specialty margins as the commodity solvents shrink away. What breaks it is a fourth straight year of write-offs or a margin that slides back under 30%. The pair to watch is quarterly revenue above $490M and gross margin above 30%. Hold both for two more quarters and the cash yield is the real thing; miss either and this was destocking wearing a recovery's clothes.

Methodology: This is a back-of-napkin rough cut, not a research report. It anchors on price/value asymmetry and verifiable business linchpins, not consensus forecasts. No price target, no rating, no recommendation.

The headline multiple uses adjusted TTM EPS of $3.27 (sum of the last four reported adjusted quarters); GAAP TTM EPS is roughly $1.14 and P/E near 64x, distorted by four years of restructuring and impairment charges. EV/EBITDA and FCF metrics are the cleaner cyclical reads.

No twelve-year P/E band was available this run, so the valuation history uses the company's own price record: average closes of $89 to $101 across 2021-2024 against $73 today.

Sector frame: specialty chemicals off a mid-cycle trough; the asymmetry is a 9.7% free-cash-flow yield against near-zero reported earnings, resolved by whether gross margin holds above 30%.

Fact check: 4 errors corrected (Q2 2026 gross margin 31.2%→30.5%, FY2026 9M EPS $0.44→$0.43, TTM revenue $1.87B→$1.84B, CEO comp claim clarified to FY2024 against positive earnings not loss). All quarterly/annual financials, margins, buyback records, and cash metrics reconciled to FMP; CEO comp from DEF 14A data. Verified Sep 7, 2026.